Table of Contents Author Guidelines Submit a Manuscript
Pain Research and Management
Volume 2018, Article ID 5704128, 4 pages
https://doi.org/10.1155/2018/5704128
Clinical Study

Accuracy of Patient Opioid Use Reporting at the Time of Medical Cannabis License Renewal

1Department of Psychology, University of New Mexico, Albuquerque, NM, USA
2Department of Economics, University of New Mexico, Albuquerque, NM, USA
3Industrial Rehabilitation Clinics, Albuquerque, NM, USA

Correspondence should be addressed to Jacob M. Vigil; ude.mnu@jligiv

Received 27 October 2017; Accepted 11 January 2018; Published 28 January 2018

Academic Editor: Gokhan Zengin

Copyright © 2018 Jacob M. Vigil et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. CDC, Wide-Ranging Online Data for Epidemiologic Research (WONDER), CDC, National Center for Health Statistics, Atlanta, GA, USA, 2016, http://wonder.cdc.gov.
  2. R. A. Rudd, P. Seth, F. David, and L. Scholl, “Increases in drug and opioid-involved overdose deaths—United States, 2010–2015,” Morbidity and Mortality Weekly Report, vol. 65, pp. 1445–1452, 2016. View at Publisher · View at Google Scholar
  3. Y. L. Hurd, “Cannabidiol: swinging the marijuana pendulum from ‘weed’ to medication to treat the opioid epidemic,” Trends in Neurosciences, vol. 40, no. 3, pp. 124–127. View at Publisher · View at Google Scholar · View at Scopus
  4. G. G. Macedonio, A. Stefanucci, C. Maccallini, S. Mirzaie, E. Novellino, and A. Mollica, “Hemopressin peptides as modulators of the endocannabinoid system and their potential applications as therapeutic tools,” Protein and Peptide Letters, vol. 23, no. 12, pp. 1045–1051, 2016. View at Publisher · View at Google Scholar · View at Scopus
  5. A. Mollica, S. Pelliccia, V. Famiglini et al., “Exploring the first Rimonabant analog-opioid peptide hybrid compound, as bivalent ligand for CB1 and opioid receptors,” Journal of Enzyme Inhibition and Medicinal Chemistry, vol. 32, no. 1, pp. 444–451, 2017. View at Publisher · View at Google Scholar · View at Scopus
  6. S. Haroutounian, Y. Ratz, Y. Ginosar et al., “The effect of medicinal cannabis on pain and quality-of-life outcomes in chronic pain: a prospective open-label study,” Clinical Journal of Pain, vol. 32, no. 12, pp. 1036–1043, 2016. View at Publisher · View at Google Scholar · View at Scopus
  7. B. J. Piper, R. M. DeKeuster, M. L. Beals et al., “Substitution of medical cannabis for pharmaceutical agents for pain, anxiety, and sleep,” Journal of Psychopharmacology, vol. 31, no. 5, pp. 569–575, 2017. View at Publisher · View at Google Scholar · View at Scopus
  8. S. E. McCabe, B. T. West, C. J. Teter, and C. J. Boyd, “Trends in medical use, diversion, and nonmedical use of prescription medications among college students from 2003 to 2013: connecting the dots,” Addictive Behaviors, vol. 39, no. 7, pp. 1176–1182, 2014. View at Publisher · View at Google Scholar · View at Scopus
  9. T. Ives, P. Chelminski, C. Hammett-Stabler et al., “Predictors of opioid misuse in patients with chronic pain: a prospective cohort study,” BMC Health Services Research, vol. 6, p. 46, 2006. View at Publisher · View at Google Scholar · View at Scopus
  10. K. Kipping, C. Maier, H. H. Bussemas, and A. Schwarzer, “Medication compliance in patients with chronic pain,” Pain Physician, vol. 17, no. 1, pp. 81–94, 2014. View at Google Scholar
  11. L. Manchikanti, R. Manchukonda, K. S. Damron, D. Brandon, C. D. McManus, and K. Cash, “Does adherence monitoring reduce controlled substance abuse in chronic pain patients?” Pain Physician, vol. 9, no. 1, pp. 57–60, 2006. View at Google Scholar
  12. S. E. Melanson, M. I. Kredlow, and P. Jarolim, “Analysis and interpretation of drug testing results from patients on chronic pain therapy: a clinical laboratory perspective,” Clinical Chemistry and Laboratory Medicine, vol. 47, no. 8, pp. 971–976, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. E. Michna, R. N. Jamison, L. D. Pham et al., “Urine toxicology screening among chronic pain patients on opioid therapy: frequency and predictability of abnormal findings,” Clinical Journal of Pain, vol. 23, no. 2, pp. 173–179, 2007. View at Publisher · View at Google Scholar · View at Scopus
  14. K. E. Vowles, M. L. McEntee, P. S. Julnes, T. Frohe, J. P. Ney, and D. N. van der Goes, “Rates of opioid misuse, abuse, and addiction in chronic pain: a systematic review and data synthesis,” Pain, vol. 156, no. 4, pp. 569–576, 2015. View at Publisher · View at Google Scholar · View at Scopus
  15. J. L. Scavone, R. C. Sterling, and E. J. Van Bockstaele, “Cannabinoid and opioid interactions: implications for opiate dependence and withdrawal,” Neuroscience, vol. 248, pp. 637–654, 2013. View at Publisher · View at Google Scholar · View at Scopus
  16. M. A. Bachhuber, B. Saloner, C. O. Cunningham et al., “Medical cannabis laws and opioid analgesic overdose mortality in the United States, 1999-2010,” JAMA Internal Medicine, vol. 174, no. 10, pp. 1668–1673, 2014. View at Publisher · View at Google Scholar · View at Scopus
  17. J. H. Kim, J. Santaella-Tenorio, C. Mauro et al., “State medical cannabis laws and the prevalence of opioids detected among fatally injured drivers,” American Journal of Public Health, vol. 106, no. 11, pp. 2032–2037, 2016. View at Publisher · View at Google Scholar · View at Scopus
  18. A. C. Bradford and W. D. Bradford, “Medical cannabis laws reduce prescription medication use in medicare part D,” Health Affairs, vol. 35, no. 7, pp. 1230–1236, 2016. View at Publisher · View at Google Scholar · View at Scopus
  19. W. D. Chey, L. Webster, M. Sostek, J. Lappalainen, P. N. Barker, and J. Tack, “Naloxegol for opioid-induced constipation in patients with non-cancer pain,” New England Journal of Medicine, vol. 370, no. 25, pp. 2387–2396, 2014. View at Publisher · View at Google Scholar · View at Scopus
  20. R. Chou, J. A. Turner, E. B. Devine et al., “The effectiveness and risks of long-term opioid therapy for chronic pain: a systematic review for a National Institutes of Health Pathways to Prevention Workshop,” Annals of Internal Medicine, vol. 162, no. 4, pp. 276–286, 2015. View at Publisher · View at Google Scholar · View at Scopus
  21. S. S. Stith and J. M. V. Vigil, “Federal barriers to Cannabis research,” Science, vol. 352, no. 6290, p. 1182, 2016. View at Publisher · View at Google Scholar · View at Scopus